OnRamp Bioinformatics has integrated its flagship ROSALIND genomic data analysis software (pictured) with Active Motif’s kits and antibodies in an epigenetics collaboration aimed at improving the accuracy of data analysis for chromatin immunoprecipitation (ChIP) sequencing experiments. [OnRamp Bioinformatics]

OnRamp Bioinformatics, Active Motif Partner on ChIP-seq Data Analysis

Collaboration aimed at improving the accuracy of data analysis for chromatin immunoprecipitation (ChIP) sequencing experiments.
Doctor holding oxygen ambu bag over patient given oxygen to patient by intubation tube in ICU/Emergency room

ACE inhibitors and Angiotensin Receptor Blockers May Increase Mortality Rate In Elderly COVID-19 Patients

These highly prescribed medications change cell surface protein expression, which is particularly problematic in cells in the respiratory system—tissue that is vulnerable to targeting and attack by the COVID-19 virus.
Next-Generation Precision Medicine Research Array

Next-Generation Precision Medicine Research Array

The Axiom Precision Medicine Research Array is a powerful genotyping solution with more than 900,000 markers
Tumor profiling assays of Foundation Medicine and Caris Life Sciences will identify abnormalities qualifying a patient for personalized cancer treatment through NCI-MATCH. [Royalty Stock Photo/Shutterstock]

Foundation Medicine, Caris Assays Identify Patients for NCI-MATCH

Companies' tumor profiling assays will identify abnormalities qualifying a patient for personalized cancer treatment through NCI-MATCH.
Clinical OMICs Magazine: Volume 4

Exome Sequencing May Miss Pathogenetic Variants

While a patient may unknowingly skirt unseen dangers, like a latter-day Magoo blindly wandering past open manholes, physicians would rather patients be aware of...
Abstract DNA.

Panel Identifies Hurdles to Wider AI Use in Diagnostic, Rx Development

Artificial intelligence (AI) is gaining a foothold in the discovery and development of drugs and diagnostics—but its use in both will remain limited unless companies surmount hurdles to the technology in the next few years, a panel of industry executives agreed.
GenomeDx Biosciences has agreed to pay the U.S. federal government $1.99 million to settle allegations that it submitted false claims to Medicare for the Decipher post-operative genetic test for prostate cancer patients. [National Cancer Institute

GenomeDx to Pay $1.99M to Settle Medicare Billing Allegations

Company accused of submitting false claims to Medicare for the Decipher prostate cancer test between September 2015 and June 2017
Exome sequencing designed to identify the gene responsible for chronic kidney disease has a direct impact on treatment for most patients

CareDx Gets Medicare Draft Coverage Decision for Heart Transplant Rejection Test

Non-invasive diagnostics maker CareDx, which focuses on early detection of organ rejection in kidney and heart transplant patients, announced its blood-based test AlloSure has...
Telomeric DNA is subject to attrition due to aging

Fast/Slow Telomere Shortening Predicts Cancer

Telomere length hasn’t been a reliable yardstick for measuring the progress of cancer. Because cancer cells divide frequently, and because telomeres shorten with repeated...
Myanmar: Rhesus Macaque

CRISPR-Cas9 Used to Create Primate Model of Autism

Researchers headed by teams at the Chinese Academy of Sciences, and Massachusetts Institute of Technology (MIT), have used CRISPR-Cas9 gene editing to engineer macaque...
Scroll Up